JonesResearch analyst Soumit Roy initiated coverage of Acrivon Therapeutics with a Buy rating and $26 price target. Acrivon is a clinical stage biotech company with a proprietary proteomic-based biomarker identification platform, the analyst tells investors in a research note. The firm says the company’s lead asset is ACR-368, a CHK1/2 inhibitor, has showed monotherapy activity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRV:
- Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Therapeutics expects cash to fund operations into 2025
- Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Acrivon Therapeutics announces anticipated milestones
- Acrivon Therapeutics reports Q2 EPS (64c), consensus (65c)